Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer - Clinical Oncology

Department of Clinical Medicine

Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer

Research output: Contribution to journal › Journal article › Research › peer-review

Documents

Fulltext
Final published version, 678 KB, PDF document

Edyta M. Urbanska
Sørensen, Jens Benn
Linea C. Melchior
Junia C. Costa
Santoni Rugiu, Eric

Original language	English
Article number	e2200040
Journal	JCO Precision Oncology
Volume	6
Issue number	6
Number of pages	6
ISSN	2473-4284
DOIs	https://doi.org/10.1200/PO.22.00040
Publication status	Published - 2022

ID: 346600551